Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AHA omega-3 statement

This article was originally published in The Tan Sheet

Executive Summary

"Evidence from prospective secondary prevention trials suggests" eicosapentaenoic acid plus docosahexaenoic acid "significantly reduce subsequent cardiac and all-cause mortality," AHA scientific statement in Nov. 19 Circulation says. Penny Kris-Etherton, PhD, et al., suggest while a dietary approach to increase omega-3 fatty acid intake "is preferable," supplements may be considered for those who cannot consume the recommended .5 g/d to 1.8 g/d through fish alone. However, researchers note "additional studies are needed to confirm and further define the health benefits of omega-3 fatty acid supplements for both primary and secondary prevention" of coronary disease. Patients taking more than 3 g of EPA + DHA from supplements "should do so only under a physician's care," Kris-Etherton et al. add...

You may also be interested in...



OMB omega-3 request

OMB urges HHS, USDA to modify the Dietary Guidelines and Food Guide Pyramid to include new information stating omega-3 fatty acids may reduce the risk of coronary heart disease, while trans fatty acids may increase risk of CHD, according to May 28 1"prompt" letter. OMB bases its request on "epidemiologic and clinical studies finding that an increase in consumption of omega-3 fatty acids results in reduced deaths due to CHD." OMB also points to American Heart Association's recent revision of its dietary guidelines to recommend eating fish, which is high in omega-3 fatty acids, twice weekly (2"The Tan Sheet" Dec. 2, 2002, In Brief). "Prompt" letter, which is used by Bush Administration to highlight issues considered worthy of priority status, requests meeting "in the next few weeks to discuss this issue"...

Why US FDA Requested Ranitidine Withdrawal, And How Other Drugs Could Follow

FDA made request after finding unacceptable levels of nitrosamine NDMA can form during storage above room temperature or beyond expiry. Forthcoming guidance on detecting impurities like nitrosamines in any drug will call for routine testing as well as a chemical risk assessment “to look at what is the probability of generating them.

Advanced Imaging Group Calls For Swifter FDA Approvals For Mobile X-Ray, CT, Ultrasound Devices For COVID-19 Crisis

The Medical Imaging & Technology Alliance recently sent a letter to the US FDA recommending steps the agency can take to help the advanced imaging industry quickly respond to the COVID-19 outbreak.

Topics

UsernamePublicRestriction

Register

PS094836

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel